Fingolimod suppresses bone resorption in female patients with multiple sclerosis

• Published in: Journal of neuroimmunology Vol. 298; pp. 24 - 31
• Main Authors: Miyazaki, Yusei, Niino, Masaaki, Kanazawa, Ippei, Suzuki, Masako, Mizuno, Masanori, Hisahara, Shin, Fukazawa, Toshiyuki, Takahashi, Eri, Amino, Itaru, Ochi, Ryutaro, Nakamura, Masakazu, Akimoto, Sachiko, Minami, Naoya, Fujiki, Naoto, Doi, Shizuki, Shimohama, Shun, Terayama, Yasuo, Kikuchi, Seiji
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.09.2016
• Subjects: Adult; Allergy and Immunology; Bone resorption; Bone Resorption - drug therapy; Bone Resorption - etiology; Collagen Type I - urine; Disability Evaluation; Female; Fingolimod; Fingolimod Hydrochloride - therapeutic use; Humans; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; Multiple sclerosis; Multiple Sclerosis - complications; Multiple Sclerosis - drug therapy; Multiple Sclerosis - urine; Neurology; Osteoclasts; Osteoporosis; Peptide Fragments - metabolism; Peptides - urine; Procollagen - metabolism; Sex Characteristics; Sphingosine-1-phosphate; Tartrate-Resistant Acid Phosphatase - metabolism; RANKL; Multiple sclerosis; Fingolimod; MS; S1PR; P1NP; uNTX; ECLIA; IFN; Bone resorption; BAP; Osteoporosis; S1P; TRACP; Sphingosine-1-phosphate; Osteoclasts; HC; EIA; UT; BMI; EDSS; sphingosine-1-phosphate receptor; electro-chemiluminescence immunoassay; expanded disability status scale; bone-specific alkaline phosphatase; receptor activator of nuclear factor kappa-B ligand; healthy controls; untreated; multiple sclerosis; body mass index; tartrate-resistant acid phosphatase; interferon; enzyme immunoassay; urinary type I collagen cross-linked N-telopeptide; procollagen type 1 amino-terminal propeptide; sphingosine-1-phosphate
• ISSN: 0165-5728; 1872-8421; 1872-8421
• DOI: 10.1016/j.jneuroim.2016.06.007

Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N-telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients. [Display omitted] •Fingolimod suppresses bone resorption in patients with MS.•Suppression of bone resorption by fingolimod is prominent in female MS patients.•Fingolimod may have a beneficial effect on bone mass loss in female MS patients.